Jing Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jing Zhang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Dixuan Jiang
Department of Respiratory Medicine, The First Hospital of Changsha City, No.311 Yingpan Road, Kaifu District, Changsha, 410005, Hunan Province, China
1 shared publication - Fang Zheng
The First Hospital of Changsha, Changsha, China
1 shared publication - Hong Peng
Department of Respiratory Medicine The Second Xiangya Hospital affiliated with Central South University Changsha Hunan China
1 shared publication - Ji-Yang Liu
The First Hospital of Changsha, 410000, Changsha, Hunan, China
1 shared publication - Ke-Yu Li
Department of Respiratory Medicine The First Hospital of Changsha Changsha Hunan China
1 shared publication - Lei Zhang
Tianjin Medical University Cancer Institute and Hospital, 300000, Tianjin, China
1 shared publication
Latest Publications
- Open Access
- 4 March 2020
- Published by MDPI AG in Preprints.org
Short-Term Moderate-Dose Corticosteroid Plus Immunoglobulin Effectively Reverses COVID-19 Patients Who Have Failed Low-Dose Therapy
Background: The coronavirus disease-19 (COVID-19) has spread globally with more than 80,000 people infected, and nearly 3000 patients died. Currently, we are in an urgent need for effective treatment strategy to control the clinical deterioration of COVID-19 patients. Methods: The clinical data of 10 COVID-19 patients receiving short-term moderate-dose corticosteroid (160mg/d) plus immunoglobulin (20g/d) were studied in the North Yard of The First Hospital of Changsha, Hunan from January 17th to February 27th, 2020. Epidemiological, clinical, laboratory, radiological findings were analyzed. Results: After treatment with combination of low-dose corticosteroid (40-80mg/d) and immunoglobulin (10g/d), patients’ lymphocyte count (0.88±0.34 vs 0.59±0.18, P2 (94.90±2.51 vs 90.50±5.91, P2/FiO2 (321.36±136.91 vs 129.30±64.97, P2 (90.50±5.91 vs 97.50±1.18, P2 (60.47±14.53 vs 99.07±34.31, P2/FiO2 (129.30±64.97 vs 340.86±146.72, P Conclusions: Short-term moderate-dose corticosteroid plus immunoglobulin is effective for reversing the continued deterioration of COVID-19 patients who failed to respond to the low-dose therapy. Funding: This work was supported by the Innovative Major Emergency Project Funding against the New Coronavirus Pneumonia in Hunan Province (Dr. Ji-Yang Liu, number 2020SK3014; Dr. Yuan-Lin Xie, number 2020SK3013).
- 4 March 2020
- Published by MDPI AG in Preprints.org
Open AccessShort-Term Moderate-Dose Corticosteroid Plus Immunoglobulin Effectively Reverses COVID-19 Patients Who Have Failed Low-Dose Therapy
Background: The coronavirus disease-19 (COVID-19) has spread globally with more than 80,000 people infected, and nearly 3000 patients died. Currently, we are in an urgent need for effective treatment strategy to control the clinical deterioration of COVID-19 patients. Methods: The clinical data of 10 COVID-19 patients receiving short-term moderate-dose corticosteroid (160mg/d) plus immunoglobulin (20g/d) were studied in the North Yard of The First Hospital of Changsha, Hunan from January 17th to February 27th, 2020. Epidemiological, clinical, laboratory, radiological findings were analyzed. Results: After treatment with combination of low-dose corticosteroid (40-80mg/d) and immunoglobulin (10g/d), patients’ lymphocyte count (0.88±0.34 vs 0.59±0.18, P2 (94.90±2.51 vs 90.50±5.91, P2/FiO2 (321.36±136.91 vs 129.30±64.97, P2 (90.50±5.91 vs 97.50±1.18, P2 (60.47±14.53 vs 99.07±34.31, P2/FiO2 (129.30±64.97 vs 340.86±146.72, P Conclusions: Short-term moderate-dose corticosteroid plus immunoglobulin is effective for reversing the continued deterioration of COVID-19 patients who failed to respond to the low-dose therapy. Funding: This work was supported by the Innovative Major Emergency Project Funding against the New Coronavirus Pneumonia in Hunan Province (Dr. Ji-Yang Liu, number 2020SK3014; Dr. Yuan-Lin Xie, number 2020SK3013).